{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:49:33Z","timestamp":1762530573429,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007210","name":"Varian Medical Systems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.adro.2022.101156","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T02:20:30Z","timestamp":1672280430000},"page":"101156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Determining Combined Modality Dosimetric Constraints by Integration of IMRT and LDR Prostate Brachytherapy Dosimetry and Correlation with Toxicity"],"prefix":"10.1016","volume":"8","author":[{"given":"Adam C.","family":"Riegel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason D.","family":"Nosrati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baho U.","family":"Sidiqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yen-Ruh","family":"Wuu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucille","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Potters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2022.101156_bib0001","unstructured":"National Cancer Institute. Cancer stat facts: Prostate cancer. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. Accessed April 29, 2022."},{"key":"10.1016\/j.adro.2022.101156_bib0002","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.brachy.2015.02.389","article-title":"Combination therapy improves prostate cancer survival for patients with potentially lethal prostate cancer: The impact of Gleason pattern 5","volume":"14","author":"Liss","year":"2015","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2022.101156_bib0003","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bju.12514","article-title":"Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer","volume":"114","author":"Spratt","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.adro.2022.101156_bib0004","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijrobp.2008.04.038","article-title":"Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy","volume":"73","author":"Stone","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101156_bib0005","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1111\/j.1464-410X.2009.08661.x","article-title":"Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy","volume":"104","author":"Stock","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.adro.2022.101156_bib0006","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/cncr.27784","article-title":"The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer","volume":"119","author":"Shilkrut","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2022.101156_bib0007","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","article-title":"Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT trial): An analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost f","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101156_bib0008","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: An analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101156_bib0009","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijrobp.2017.02.027","article-title":"ASCENDE-RT: An analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost with dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101156_bib0010","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/cncr.11595","article-title":"Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy","volume":"98","author":"Albert","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2022.101156_bib0011","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bju.14128","article-title":"Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy","volume":"121","author":"Schlussel Markovic","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.adro.2022.101156_bib0012","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1002\/cncr.24558","article-title":"Radiation dose escalation for localized prostate cancer: Intensity-modulated radiotherapy versus permanent transperineal brachytherapy","volume":"115","author":"Wong","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2022.101156_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brachy.2016.09.006","article-title":"American Brachytherapy Society Task Group report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer","volume":"16","author":"Spratt","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2022.101156_bib0014","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jmir.2018.09.010","article-title":"Combined low dose rate brachytherapy and external beam radiation therapy for intermediate-risk prostate cancer","volume":"50","author":"Chao","year":"2019","journal-title":"J Med Imaging Radiat Sci"},{"key":"10.1016\/j.adro.2022.101156_bib0015","article-title":"Treatment outcomes and morbidity following definitive brachytherapy with or without external beam radiation for the treatment of localized prostate cancer: 20-year experience at Mount Sinai Medical Center","volume":"32","author":"Marshall","year":"2014","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.adro.2022.101156_bib0016","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brachy.2014.06.008","article-title":"Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: Outcomes of 1300 patients","volume":"14","author":"Yorozu","year":"2015","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2022.101156_bib0017","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.brachy.2022.07.002","article-title":"Integrating external beam and prostate seed implant dosimetry for intermediate and high-risk prostate cancer using biologically effective dose: Impact of image registration technique","volume":"21","author":"Riegel","year":"2022","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2022.101156_bib0018","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0360-3016(95)00521-Y","article-title":"A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation","volume":"32","author":"Stock","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"year":"2006","series-title":"Radiobiology for the Radiologist","author":"Hall","key":"10.1016\/j.adro.2022.101156_bib0019"},{"key":"10.1016\/j.adro.2022.101156_bib0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1259\/0007-1285-62-735-241","article-title":"Radiobiological assessment of permanent implants using tumour repopulation factors in the linear-quadratic model","volume":"62","author":"Dale","year":"1989","journal-title":"Br J Radiol"},{"key":"10.1016\/j.adro.2022.101156_bib0021","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1118\/1.3246613","article-title":"AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137","volume":"36","author":"Nath","year":"2009","journal-title":"Med Phys"},{"key":"10.1016\/j.adro.2022.101156_bib0022","unstructured":"Guest D, Riegel AC. SU-I-GPD-T-35: An algorithm to calculate biologically effective dose distributions for low dose rate prostate brachytherapy. Paper presented at: 59th Annual Meeting & Exhibition of the AAPM. July 30-August 3, 2017; Denver, CO."},{"key":"10.1016\/j.adro.2022.101156_bib0023","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1120\/jacmp.v13i5.3800","article-title":"Providing a fast conversion of total dose to biological effective dose (BED) for hybrid seed brachytherapy","volume":"13","author":"Pritz","year":"2012","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.adro.2022.101156_bib0024","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.oraloncology.2012.01.004","article-title":"Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma","volume":"48","author":"Liu","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.adro.2022.101156_bib0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","article-title":"Common toxicity criteria: Version 2.0. An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy","volume":"47","author":"Trotti","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2022.101156_bib0026","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1200\/JCO.2007.12.4784","article-title":"Patient-reported outcomes and the evolution of adverse event reporting in oncology","volume":"25","author":"Trotti","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2022.101156_bib0027","unstructured":"VassarStats. VassarStats: Website for statistical computation. Available at: http:\/\/vassarstats.net\/. Accessed July 27, 2022."},{"key":"10.1016\/j.adro.2022.101156_bib0028","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S1538-4721(02)00006-5","article-title":"Preliminary toxicity and prostate-specific antigen response of a Phase I\/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer","volume":"1","author":"Stock","year":"2002","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2022.101156_bib0029","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.brachy.2011.06.008","article-title":"American Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer","volume":"11","author":"Beriwal","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2022.101156_bib0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5114\/jcb.2019.82999","article-title":"Comparative analysis of image-guided adaptive interstitial brachytherapy and intensity-modulated arc therapy versus conventional treatment techniques in cervical cancer using biological dose summation","volume":"11","author":"Fr\u00f6hlich","year":"2019","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.adro.2022.101156_bib0031","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.21037\/tcr-20-1196","article-title":"Assessing cumulative dose distributions in combined external beam radiotherapy and intracavitary brachytherapy for cervical cancer by treatment planning based on deformable image registration","volume":"9","author":"Zeng","year":"2020","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.adro.2022.101156_bib0032","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.brachy.2016.12.006","article-title":"Deformable image registration for cervical cancer brachytherapy dose accumulation: Organ at risk dose\u2013volume histogram parameter reproducibility and anatomic position stability","volume":"16","author":"Flower","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2022.101156_bib0033","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1016\/j.prro.2019.06.003","article-title":"Appropriate methodology for EBRT and HDR intracavitary\/interstitial brachytherapy dose composite and clinical plan evaluation for patients with cervical cancer","volume":"9","author":"Xu","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.adro.2022.101156_bib0034","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5114\/jcb.2020.100379","article-title":"Biological dose summation of external beam radiotherapy for the whole breast and image-guided high-dose-rate interstitial brachytherapy boost in early-stage breast cancer","volume":"12","author":"Fr\u00f6hlich","year":"2020","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.adro.2022.101156_bib0035","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13014-016-0719-2","article-title":"Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: Dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications","volume":"11","author":"Moulton","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2022.101156_bib0036","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.meddos.2009.05.001","article-title":"Generation of composite dose and biological effective dose (BED) over multiple treatment modalities and multistage planning using deformable image registration","volume":"35","author":"Zhang","year":"2010","journal-title":"Med Dosim"},{"key":"10.1016\/j.adro.2022.101156_bib0037","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.meddos.2003.09.005","article-title":"Biological effective dose for comparison and combination of external beam and low-dose rate interstitial brachytherapy prostate cancer treatment plans","volume":"29","author":"Jani","year":"2004","journal-title":"Med Dosim"},{"key":"10.1016\/j.adro.2022.101156_bib0038","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.radonc.2013.03.003","article-title":"Three-dimensional summation of rectal doses in brachytherapy combined with external beam radiotherapy for prostate cancer","volume":"107","author":"Kikuchi","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2022.101156_bib0039","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.brachy.2010.08.007","article-title":"A simple method for dose fusion from multimodality treatment of prostate cancer: Brachytherapy to external beam therapy","volume":"10","author":"Cao","year":"2011","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2022.101156_bib0040","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.brachy.2017.10.008","article-title":"Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy","volume":"17","author":"Ferro","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2022.101156_bib0041","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.prnil.2018.03.005","article-title":"Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review","volume":"6","author":"Feutren","year":"2018","journal-title":"Prostate Int"},{"key":"10.1016\/j.adro.2022.101156_bib0042","doi-asserted-by":"crossref","first-page":"193","DOI":"10.5114\/jcb.2018.76881","article-title":"Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy","volume":"10","author":"Chapman","year":"2018","journal-title":"J Contemp Brachytherapy"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109422002627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109422002627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:42:54Z","timestamp":1762530174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109422002627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2452109422002627"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2022.101156","relation":{},"ISSN":["2452-1094"],"issn-type":[{"type":"print","value":"2452-1094"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determining Combined Modality Dosimetric Constraints by Integration of IMRT and LDR Prostate Brachytherapy Dosimetry and Correlation with Toxicity","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2022.101156","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101156"}}